Bloomberg
MEDLINE BUYOUT COULD SET OFF WAVE OF PRIVATE EQUITY INVESTMENT: While the healthcare supply chain hasn't been the primary target of private equity firms, the COVID-19 pandemic underscored the importance of a resilient supply of personal protective equipment and excess distribution capacity. Experts suggest that the Medline deal is just the beginning.
"I think this is the start of an explosion of private equity deals in healthcare," Richard Scheffler, health economics professor at UC Berkeley, tells Modern Healthcare, adding that he wouldn't be surprised if investment increases by 30% to 40% next year. "Everyone made a bundle in the Trump stock market; these firms are sitting there with capital and have to do something with it.